Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma
November 1, 2023
Resolian, a global bioanalytical contract research organization headquartered in Malvern, Pennsylvania, has acquired Denali Medpharma, a Chongqing-based bioanalytical CRO. The acquisition expands Resolian's global lab footprint and adds Denali's oligonucleotide, mRNA, and liposomal bioanalysis capabilities to Resolian's service offerings.
- Buyers
- Resolian
- Targets
- Denali Medpharma
- Industry
- Healthcare Services
- Location
- Chongqing, China
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Altos Labs Acquires Dorian Therapeutics
May 23, 2025
Biotechnology
Altos Labs has acquired Stanford spinout Dorian Therapeutics, a preclinical senotherapeutics startup developing small-molecule "senoblockers." Financial terms were not disclosed; Altos said the deal broadens its cellular rejuvenation capabilities by adding Dorian’s epigenetic senescence-targeting technology and preclinical programs in lung fibrosis and osteoarthritis.
-
PharmaLegacy Laboratories Acquires San Diego-Based BTS Research
September 16, 2024
Healthcare Services
PharmaLegacy Laboratories has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO), expanding PharmaLegacy's in vitro and in vivo pharmacology and GLP toxicology capabilities. The acquisition gives PharmaLegacy a local presence in San Diego to increase study capacity and support clients across the United States and North America.
-
Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities
July 11, 2023
Biotechnology
Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.
-
Discovery Life Sciences Acquires ReachBio Research Labs
April 11, 2023
Biotechnology
Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.
-
Chugai Pharmaceutical to Acquire Renalys Pharma
October 24, 2025
Biotechnology
Chugai Pharmaceutical Co., Ltd. will acquire Renalys Pharma, Inc. through a definitive stock purchase agreement. The transaction includes an upfront payment of JPY 15.0 billion and potential earn-outs of up to JPY 16.0 billion tied to regulatory and sales milestones for sparsentan in Japan, South Korea, and Taiwan.
-
Asahi Kasei Medical to Acquire Bionova Scientific
April 14, 2022
Healthcare Services
Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.